ArticleMedicine2025
Exploring the mechanism of action of Phyllanthus emblica in the treatment of epilepsy based on network pharmacology and molecular docking.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Neuroinflammation in Epilepsy: Biochemical and Molecular Mechanisms and Implications for Natural Product-Driven Drug Discovery.International journal of molecular sciences · 2026Review
- Ethnopharmacological relevance of Chinese medicinal materials and natural products in epilepsy: a critical multi-target review integrating neurons, glia and inflammatory signaling.Frontiers in pharmacology · 2026Review
- Limonin alleviates pyroptosis and inflammatory responses in cardiomyocytes of myocardial ischemia-reperfusion mice by inhibiting the caspase-3/GSDME pathway.Frontiers in immunology · 2026Article
- TheCurrent issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study explores the mechanism of Phyllanthus emblica in treating epilepsy (EP) through network pharmacology and molecular docking. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform identified the chemical composition of P emblica, Swiss ADME screened active components, and Swiss Target Prediction predicted targets. EP-related targets were identified using Gene Cards, OMIM, Drug Bank, TTD, and DisGeNET, and Venny 2.1.0 was used to find intersecting targets. Protein-protein interaction network analysis was conducted with STRING and Cytoscape. Chem 3D and Pymol were used for structural optimization and molecular docking was performed with AutoDock Tools 1.5.7 and Vina. Fifty-three active components and 126 intersecting targets were identified. Gene Ontology analysis revealed 3416 biological processes, 287 cellular components, and 457 molecular functions. Kyoto Encyclopedia of Genes and Genomes pathways showed neuroactive ligand-receptor interactions, nitrogen metabolism, and serotonergic synapses as key pathways. Molecular docking indicated strong binding energies between P emblica core components and targets, especially 2-ethylhexyl ester with MAPK3, luteolin with SRC, and kaempferol with MAPK1. This study explores the therapeutic potential of P emblica in treating EP through network pharmacology and molecular docking. A total of 53 active components were identified, with key compounds like 2-ethylhexyl ester, phyllanthin, luteolin, and kaempferol targeting critical proteins such as SRC, AKT1, APP, MAPK3, and MAPK1. These targets are involved in pathways related to synaptic transmission, oxidative stress, and inflammation, indicating potential neuroprotective and anti-inflammatory effects. Gene Ontology analysis highlighted the regulation of synaptic activity, while Kyoto Encyclopedia of Genes and Genomes pathway analysis emphasized pathways like neuroactive ligand-receptor interactions and serotonergic synapses. Molecular docking demonstrated strong binding affinities between active components and core targets, supporting the effectiveness of P emblica in modulating neuronal excitability and reducing neuroinflammation. These findings provide a theoretical basis for its clinical application in EP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.